Avastin for Post-photocoagulation Macular Edema
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00801866
- Phase
- PHASE4
- Status
- Withdrawn
Conditions
- Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 15 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGIntravitreal administration
- Panretinal Photocoagulation — PROCEDUREPanretinal Photocoagulation
Study Details
to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision
Key Dates
- First listed
- Dec 4, 2008
- Start date
- Dec 31, 2008
- Status verified
- May 2024
- Primary completion
- Dec 31, 2008
- Completion
- Dec 31, 2008
Study Design
- Enrollment
- 0 participants (actual)
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1Panretinal Photocoagulation + Bevacizumab
- Experimental: Group 2Panretinal Photocoagulation
Primary Outcome Measure
Best Corrected Visual Acuity
Related Studies
- A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPHASE2 · Recruiting · Boehringer Ingelheim · Arcadia, California